Provexis PLC
NZCA
Company Profile
Business description
Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.
Contact
2 Blagrave Street
I Ford
ReadingBerkshireRG1 1AZ
GBRT: +44 7490391888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.30 | 4.20 | 0.05% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,072.24 | 583.65 | 1.20% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,454.03 | 679.39 | 1.29% |
| NZX 50 Index | 13,520.11 | 53.82 | -0.40% |
| S&P 500 | 6,873.77 | 76.91 | 1.13% |
| S&P/ASX 200 | 8,841.60 | 5.70 | 0.06% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |